Home > Knowledge Hub > COVID-19 Guidance & Advice > A joint statement on vaccination for Sars-CoV2 in patients with liver disease

A joint statement on vaccination for Sars-CoV2 in patients with liver disease

Updated on: 13 Jan 2021   First published on 08 Jan 2021

A joint statement from British Society of Gastroenterology, British Association for the Study of the Liver, NHS Blood & Transplant and British Liver Trust

Patients with liver disease that are considered to be clinically extremely vulnerable are at increased risk if they contract COVID-19. This advice refers to this group and to all other patients with liver disease.

    • Whilst the vaccine trials have not looked specifically at safety in patients with liver disease, there is no data to suggest harm
    • Although vaccines may be less effective in patients with chronic liver disease and those post-liver transplant, they still provide protection. As yet there is no data specifically on the Sars-CoV2 vaccines

 

    • We recommend that patients with chronic liver disease, autoimmune hepatitis and those post-liver transplant should consider vaccination for Sars-CoV2 with any of the available vaccines

 


Login to your BSG member account to read and post comments on this page